Surgery Partners stock drops 42.4% on slowing growth & high debt. Valuation at 61.9x P/E looks risky.
Iran trolls Trump's market signals, causing $3T swings. Volatility spikes, fundamentals ignored.
SCI's 0.9% return & 19.7x P/E signal caution. Declining ROIC & weak FCF limit upside.
Visteon's 24.5% drop to $91.38 signals weak revenue & EPS. Fair 10.7x P/E, but risks loom.
March payrolls beat estimates with 178K jobs added, unemployment at 4.3%. Healthcare leads gains.
MCO drops 8.7%, but boasts 63.1% ROE & 22.8% EPS growth. Is 26.2x P/E a buy?
WTS & ATI show strong 2025 growth (17% EPS, 51% cash flow) amid market rotation. Risks exist, but tangible demand drives value.
Sponsored
Must Read